Patents Examined by Brad Duffy
  • Patent number: 10934353
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 2, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Patent number: 10934363
    Abstract: The present application provides single-domain antibodies, and chimeric antigen receptors comprising one or more antigen binding domains each comprising a single-domain antibody. Further provided are engineered immune effector cells (such as T cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 2, 2021
    Assignee: Legend Biotech USA Inc.
    Inventors: Xiaohu Fan, Chuan-Chu Chou, Qiuchuan Zhuang, Pingyan Wang, Lin Wang, Lei Yang, Jiaying Hao
  • Patent number: 10927180
    Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: February 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • Patent number: 10919983
    Abstract: The invention provides methods for generating human antibodies with the specificity of a reference antibody by replacement of portions of the VH and VL sequences of the reference antibody with sequences from human antibody repertoires. The invention also provides novel compositions comprising hybrid immunoglobulin variable domains containing a combination of frameworks (FRs) and CDRs from different antibody clones.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: February 16, 2021
    Assignee: HUMANIGEN, INC.
    Inventors: Christopher Robert Bebbington, Kenneth R. Luehrsen, Geoffrey T. Yarranton
  • Patent number: 10906991
    Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: February 2, 2021
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Rob Aalberse, Marijn Van Der Neut Kolfschote, Paul Parren
  • Patent number: 10906956
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor (e.g., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: February 2, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • Patent number: 10870702
    Abstract: Provided herein is a method for determining cancer treatment using an immune modulating therapy in a subject in need thereof. The method comprises assessing whether a lymphatic system in a subject is dysregulated. When the lymphatic system is dysregulated, a treatment for the lymphatic system is determined before a therapeutic amount of an immune modulating therapy is administered to treat cancer in the subject. Alternatively, when the lymphatic system is dysregulated, an immune modulating therapy is selected to treat cancer in the subject, which immune modulating therapy is independent of immune-cell priming, antigen trafficking, antigen presentation, and any combination thereof. The subject may also be treated for cancer accordingly.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: December 22, 2020
    Assignee: ENSEMLBLE GROUP HOLDINGS
    Inventors: Michael David Kuo, Ching-Yu Huang
  • Patent number: 10851149
    Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family ?-receptor 4 (GFR?4).
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: December 1, 2020
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, NOVARTIS AG, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Donald L. Siegel, Michael C. Milone, Vijay Bhoj, Christoph Rader
  • Patent number: 10844124
    Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 24, 2020
    Assignee: Arch Oncology, Inc.
    Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
  • Patent number: 10836830
    Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: November 17, 2020
    Assignees: AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
  • Patent number: 10821116
    Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: November 3, 2020
    Assignee: VECTURA GMBH
    Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
  • Patent number: 10822380
    Abstract: As disclosed herein, stapled peptides targeting the interaction interface between proteins that maintain the integrity of Wiskott-Aldrich syndrome protein family member 3 (WASF3) leads to destabilization of WASF3 and suppression of invasion. Disclosed are stapled peptides that inhibit the binding of Cytoplasmic FMR1-interacting protein 1 (CYFIP1) to either WASF3 or NCK-associated protein (NCKAP1). Also disclosed are methods for treating or suppressing invasion and metastasis of a cancer in a subject that involve administering to the subject a therapeutically effective amount of a stapled peptide disclosed herein.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: November 3, 2020
    Assignees: University of Georgia Research Foundation, Inc., Augusta University Research Institute, Inc.
    Inventors: Eileen J. Kennedy, John Cowell
  • Patent number: 10808031
    Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: October 20, 2020
    Assignee: Cancer Research Technology Limited
    Inventors: Roy Bicknell, Peter Noy, Kabir Ali Khan
  • Patent number: 10799584
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of an alkylating agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: October 13, 2020
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh Saha, Xiaoyan M. Zhang, Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire
  • Patent number: 10781249
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: September 22, 2020
    Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.
    Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
  • Patent number: 10768170
    Abstract: Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: September 8, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Jeffrey S. Weber, Wenshi Wang, Bin Yu
  • Patent number: 10766968
    Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: September 8, 2020
    Assignee: BROWN UNIVERSITY
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
  • Patent number: 10758614
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a topoisomerase inhibitor; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: September 1, 2020
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, Biomed Valley Discoveries, Inc.
    Inventors: Saurabh Saha, Xiaoyan M. Zhang, Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire
  • Patent number: 10759859
    Abstract: A subset of humanized anti-PD-1 antibodies that inhibit binding of PD-L1 and PD-L2 to human PD-1. These binding proteins modulate the immune system through the manipulation of the PD-1 signaling pathway to treat immune dysfunctional disorders, including for example cancers.
    Type: Grant
    Filed: January 14, 2017
    Date of Patent: September 1, 2020
    Assignee: BPS Bioscience, Inc.
    Inventors: Xiaohui Yuan, Aaron Snead, Zhihua Tao, Kim Skuster, Colin Cowdrey, Jonathan Mikolosko, Andrew Newman, Henry Zhu
  • Patent number: 10759868
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 1, 2020
    Assignee: CELLECTIS
    Inventor: Cècile Schiffer-Mannioui